Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Price:
69.12 CNY
-1.58%
Updated:
May 8, 2024
Income Statement
Earnings Waterfall
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
|
Revenue
|
5.5B
CNY
|
|
Cost of Revenue
|
-992.7m
CNY
|
|
Gross Profit
|
4.5B
CNY
|
|
Operating Expenses
|
-3.1B
CNY
|
|
Operating Income
|
1.4B
CNY
|
|
Other Expenses
|
-158.6m
CNY
|
|
Net Income
|
1.2B
CNY
|
Income Statement
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Revenue |
1 599
N/A
|
2 354
+47%
|
2 867
+22%
|
3 474
+21%
|
4 351
+25%
|
5 750
+32%
|
8 098
+41%
|
9 716
+20%
|
10 805
+11%
|
11 185
+4%
|
10 901
-3%
|
9 419
-14%
|
7 504
-20%
|
5 511
-27%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(323)
|
(471)
|
(497)
|
(570)
|
(647)
|
(848)
|
(1 051)
|
(1 211)
|
(1 270)
|
(1 191)
|
(1 138)
|
(984)
|
(899)
|
(993)
|
|
| Gross Profit |
1 277
N/A
|
1 883
+48%
|
2 370
+26%
|
2 904
+23%
|
3 704
+28%
|
4 903
+32%
|
7 047
+44%
|
8 506
+21%
|
9 535
+12%
|
9 994
+5%
|
9 763
-2%
|
8 435
-14%
|
6 605
-22%
|
4 518
-32%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(725)
|
(1 103)
|
(1 344)
|
(1 588)
|
(2 127)
|
(2 580)
|
(3 421)
|
(3 770)
|
(3 931)
|
(4 507)
|
(4 509)
|
(4 336)
|
(3 910)
|
(3 112)
|
|
| Selling, General & Administrative |
(551)
|
(808)
|
(1 008)
|
(1 229)
|
(1 552)
|
(1 940)
|
(2 778)
|
(3 122)
|
(3 453)
|
(3 585)
|
(3 508)
|
(3 196)
|
(2 541)
|
(1 869)
|
|
| Research & Development |
(193)
|
(300)
|
(348)
|
(389)
|
(575)
|
(658)
|
(710)
|
(711)
|
(608)
|
(1 040)
|
(1 211)
|
(1 329)
|
(1 532)
|
(1 102)
|
|
| Depreciation & Amortization |
0
|
(51)
|
0
|
0
|
0
|
(66)
|
0
|
0
|
0
|
(105)
|
0
|
0
|
0
|
(187)
|
|
| Other Operating Expenses |
20
|
56
|
12
|
29
|
0
|
84
|
66
|
63
|
130
|
223
|
210
|
189
|
163
|
45
|
|
| Operating Income |
552
N/A
|
780
+41%
|
1 026
+32%
|
1 316
+28%
|
1 577
+20%
|
2 323
+47%
|
3 626
+56%
|
4 736
+31%
|
5 604
+18%
|
5 488
-2%
|
5 254
-4%
|
4 100
-22%
|
2 695
-34%
|
1 406
-48%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
10
|
(8)
|
5
|
(5)
|
2
|
7
|
(2)
|
29
|
67
|
108
|
144
|
175
|
197
|
218
|
|
| Non-Reccuring Items |
0
|
3
|
1
|
0
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
(222)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(1)
|
|
| Total Other Income |
(10)
|
(11)
|
(12)
|
(5)
|
(1)
|
(4)
|
(5)
|
(6)
|
(7)
|
(11)
|
(13)
|
(13)
|
(13)
|
(7)
|
|
| Pre-Tax Income |
552
N/A
|
765
+39%
|
1 019
+33%
|
1 307
+28%
|
1 579
+21%
|
2 324
+47%
|
3 619
+56%
|
4 758
+31%
|
5 664
+19%
|
5 583
-1%
|
5 385
-4%
|
4 262
-21%
|
2 879
-32%
|
1 393
-52%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(81)
|
(83)
|
(118)
|
(145)
|
(154)
|
(245)
|
(443)
|
(628)
|
(759)
|
(719)
|
(656)
|
(468)
|
(244)
|
(147)
|
|
| Income from Continuing Operations |
471
|
682
|
901
|
1 163
|
1 425
|
2 079
|
3 176
|
4 130
|
4 905
|
4 863
|
4 729
|
3 793
|
2 636
|
1 247
|
|
| Income to Minority Interest |
(4)
|
(5)
|
(6)
|
(8)
|
(26)
|
(58)
|
(113)
|
(137)
|
(128)
|
(128)
|
(79)
|
(48)
|
(35)
|
1
|
|
| Net Income (Common) |
467
N/A
|
677
+45%
|
896
+32%
|
1 155
+29%
|
1 398
+21%
|
2 021
+45%
|
3 063
+52%
|
3 993
+30%
|
4 777
+20%
|
4 736
-1%
|
4 650
-2%
|
3 745
-19%
|
2 600
-31%
|
1 248
-52%
|
|
| EPS (Diluted) |
0.8
N/A
|
1.16
+45%
|
1.47
+27%
|
1.31
-11%
|
1.59
+21%
|
1.64
+3%
|
3.48
+112%
|
4.54
+30%
|
3.77
-17%
|
3.79
+1%
|
3.67
-3%
|
2.96
-19%
|
2.07
-30%
|
0.99
-52%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
